- Journal Article -

The Safety of Intravenous Drug Delivery Systems: Update on Current Issues Since the 1999 Consensus Development Conference (Hospital Pharmacy - Feb 2009) 

Program Description A review that was prepared in advance of the 2008 Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems to assist in evaluating the changes that have occurred in IV delivery systems since the initial Consensus Conference in 1999.

Learning Objectives

Upon completion of this activity, pharmacists will be able to:

• Explain the results from the original Consensus Development Conference on the Safety of Intravenous (IV) Drug Delivery Systems (1999).

• Compare recent standards including the United States Pharmacopeia (USP) Chapter 797, Joint Commission Medication Management, and Centers for Medicare and Medicaid Services (CMS) rule on hospital-acquired conditions.

• Describe the American Society for Parenteral and Enteral Nutrition (ASPEN) statement on standardization of parenteral nutrition solutions.

Program Faculty

Michael Gabay PharmD, JD, BCPS
Director, Drug Information Group and Prior Authorization Services
Clinical Assistant Professor, Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Mary Lynn Moody, BSPharm
Director of Business Development, Drug Information Group
Clinical Assistant Professor
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Michael Sanborn, MS, RPh, FASHP
Corporate Vice President
Baylor Health Care System
Dallas, Texas

Disclosure

It is the policy of ProCE, Inc. to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) discussed in an educational presentation. Dr. Gabay, Ms. Moody, and Mr. Sanborn have reported that they have no significant financial or commercial relationships to disclose.

Please note: The information and views presented in this CE activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs and/or devices for unlabeled indications. Use of drugs and/or devices outside of labeling should be considered experimental. Participants are advised to consult and verify manufacturer product information, the professional literature and use his/her professional judgment in applying the presented information in patient care activities.

CE Accreditation

Pharmacists:
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Program Number 221-000-09-010-H05-P has been assigned to this home study, knowledge-based activity. This program is acceptable for 1.0 contact hours (0.10 CEUs) in states that recognize ACPE providers.

Release Date: 02-14-2009
Expiration Date: 02-14-2012

Funding

This program is supported by an educational grant from Baxter Healthcare Corporation.